GLP-1 Drugs Are Wrecking Pharmacy Budgets: How Employers Are Managing Semaglutide and Tirzepatide Costs Without Banning Coverage

A $320,000 Surprise: What Happens When GLP-1 Claims Explode

Last year, I sat in a renewal meeting with a 900-employee manufacturer whose pharmacy spend ballooned to $1.7 million. Of that, $320,000, nearly 19 percent, came from just two GLP-1 drugs, semaglutide and tirzepatide. Their HR director wasn’t new to specialty drug sticker shock, but she hadn’t expected to see a handful of Ozempic and Mounjaro claims rival the combined cost of their entire diabetes and mental health drug classes.

She’s not alone. Across the mid-market, GLP-1s routinely account for 10 to 25 percent of pharmacy budgets, even when only 3 to 5 percent of members have a claim. With media buzz and direct-to-consumer advertising driving demand, HR teams find their inboxes flooded with questions about Ozempic and Wegovy. Left unchecked, members jump through insurer hoops to get scripts, and plan sponsors are left cleaning up the budget mess.

The knee-jerk reaction, “let’s just exclude GLP-1s for obesity”, is tempting, especially for smaller employers staring down six-figure increases. But a hard exclusion brings employee relations headaches and can even prompt high-value talent to jump ship. Most groups are instead looking for ways to tap the brakes without slamming the door.

Clinical Prior Authorization: More Than a Rubber Stamp

Every major PBM, CVS Caremark, Express Scripts, OptumRx, now places prior authorization requirements on GLP-1 drugs. But the actual criteria can be surprisingly thin, especially on older diabetes versions like Ozempic and Trulicity. A member with a weakly documented diagnosis may still clear the hurdle.

If your GLP-1 spend jumped by $100,000 or more in the last 12 months, ask your PBM for a clinical policy review. Several independent PBMs, including Capital Rx and Navitus, let employers customize approval criteria: documented BMI ≥30 (or ≥27 with comorbidities), failures of metformin and lifestyle modification, and annual reauthorization based on weight loss outcomes. One 700-life engineering firm added a “mandatory lifestyle program enrollment” requirement for Wegovy and Zepbound, which trimmed their GLP-1 claims by 28 percent quarter-over-quarter.

Prior authorization is only as strong as the clinical documentation you require. “Auto-approving” after one step therapy check won’t stop off-label use, especially for weight loss in non-diabetics. Tighten your criteria, insist on chart notes, and require periodic re-checks. You won’t eliminate all inappropriate use, but you can curb it enough to shift your PMPM trend line meaningfully.

Copays and Plan Design: Don’t Ignore Member Skin in the Game

Rich plan designs can turn GLP-1s into a no-brainer for anyone on the fence. I’ve seen $20 tier-2 copays for $1,100/month drugs, which just hands members a free ticket to the pharmacy. If you haven’t reviewed your plan’s specialty tiers lately, pull your data. What’s your average out-of-pocket per GLP-1 claim? If it’s under $100, you’re likely underpricing the demand.

Some self-funded clients have moved semaglutide and tirzepatide to a non-preferred specialty tier with $250-$350 copays (sometimes higher, offset with an annual OOP max). This doesn’t “ban” coverage, but it makes members consider if the spend is worth it, especially for weight loss indications not covered by all plans. In a 450-employee high tech group, this move cut their annual GLP-1 claims from 19 to 11, saving roughly $96,000 with no major member complaints.

For plans with a high-deductible structure, you can require members to meet the deductible before coinsurance kicks in for these drugs. Just make sure you’re compliant with your SPD and state or federal requirements before pushing through big mid-year changes.

Alternatives, Carve-Outs, and the Realities of Coupon Assistance

More groups are asking about “alternative savings” strategies, think copay maximizer programs, manufacturer coupon capture, or even directing members to outside resources like RxSaver.ai or Mark Cuban Cost Plus Drugs. While programs like Eli Lilly’s Insulin Value Program and Novo Nordisk’s PAP offer relief for insulin, most GLP-1 programs have strict eligibility rules and are off-limits for commercially-insured members already getting coverage.

Some specialty pharmacy vendors tout “carve-out” programs or white-glove coupon navigation, but the savings seldom match what you see with high-cost self-injectable biologics. Most manufacturer coupons for Ozempic or Wegovy cap out at $150-$500/month and typically require the plan to cover the base drug. A PBM copay maximizer approach may offer modest offset, but don’t overestimate the potential: it’s rare to see more than $4,000-$6,000 savings per member annually using these tactics for GLP-1s (compared to >$20,000/member savings with Humira biosimilars).

Employers sometimes ask about requiring members to try compounded “semaglutide” or “tirzepatide” from specialty clinics. This is risky. Compounded versions aren’t FDA approved, vary wildly in quality (see recent FDA warnings), and may expose your plan to liability. Very few stop-loss carriers will back you on a compounded-first step. Steer clear.

Communications and Data: Don’t Let GLP-1s Blindside You Next Renewal

It’s easy to miss the GLP-1 trend until it’s too late. These drugs often show up as line items in your top-10 spenders, but don’t always spike your overall GDR or generic brand mix. Review your claims every quarter, not just at renewal. Use resources like RxInfo.ai to benchmark your PMPM and identify new-to-therapy trends.

When you make changes (prior authorization, tier moves, benefit limits), over-communicate. Send targeted notices to impacted members, update your SPDs, work with your PBM or pharmacy consultant to create FAQ documents, and prep your HR team with talking points. Confusion sours employee trust and creates more noise than necessary.

If you’re part of a group health coalition or use a pharmacy benefits consultant, share de-identified data so you can see how your experience stacks up. You don’t need to ban coverage outright to get GLP-1 costs under control, but you do need a plan, and the discipline to revisit it every 12 months as new drugs, biosimilars, and clinical evidence reshape the landscape.

GLP-1s aren’t going away. If you prepare now, you’ll avoid the next $300,000 surprise.